Live feed07:00:00·38dPRReleasevia QuantisnowCullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid LeukemiaByQuantisnow·Wall Street's wire, on your screen.CGEM· Cullinan Therapeutics Inc.Health Care
